Clinical Effectiveness and Cognitive Impact of Electroconvulsive Therapy for Schizophrenia: A Large Retrospective Study Tyler S. Kaster MD, Zafiris J.

Slides:



Advertisements
Similar presentations
Depression in adults with a chronic physical health problem
Advertisements

New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Standards of Electroconvulsive Therapy (ECT) Services at Zomba Mental Hospital (ZMH) Michael M. M. Udedi.
Effects of electroconvulsive therapy for depression on health related quality of life Adam Kavanagh.
The Cochrane Reviews of Acupuncture Doris Hubbs, MD, FACP April 26, 2013.
The Behavioural/Developmental Continuum of Interventions for Autism Spectrum Disorders: A Systematic Review Many Faces of Childhood Well Being: The Early.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2009.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Evidence-based Treatment of Psychotic Depression Gregory W. Dalack, MD June 22, 2006.
PICO Deep brain stimulation for treatment resistant depression. Clinical reality ?
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
Réunion Ambulatoires SAS,  Similarly, a statistically significant MADRS reduction over time was found (F=156.2, p 800 mg/day) and low (
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 17Somatic Therapies.
Trans Cranial Magnetic Stimulation (rTMS) setting up a service in the Private sector Carol Turnbull CEO, Ramsay Health Care SA Mental Health services APHA.
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
The Clinical Antipsychotic Trials of Intervention Effectiveness Trial
Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A VERITY Registry Study Denise O'Shaughnessy, Peter Rose,
It’s Possible to prevent social exclusion among mentally ill?: IPSE Project, " Clinical Case Management " in Schizophrenic Patients in two catchment areas.
Psychopharmacology – A brief introduction. Objectives Review general categories of psychiatric disorders Review general categories of psychiatric disorders.
Treatment for Adolescents With Depression Study (TADS)
Presenter: Tyler Kaster Supervisor: Zafiris Daskalakis
Interferences between depression and life quality on patients suffering of type 2 diabetes First Author : Madalina Crisan Coauthors: Madalina Salagean.
10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.
“The Effect of Patient Complexity on Treatment Outcomes for Patients Enrolled in an Integrated Depression Treatment Program- a Pilot Study” Ryan Miller,
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Pharmacotherapy in Psychotic Disorders. Antipsychotic drugs Treat the symptoms of the disorder Do not cure schizophrenia Include two major classes: –
Alan Breier, M.D. Leader, Zyprexa Product Team Lilly Research Fellow Professor of Psychiatry, Indiana University School of Medicine Adjunct Associate of.
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Ron Beasley, PharmD Candidate Preceptor: Soheyla Mahdavian, PharmD
A media webinar co-hosted by the Science Media Centre of Canada Brain stimulation therapies for mental illness.
A Randomised, Controlled Trial of Acetaminophen, Ibuprofen, and Codeine for Acute Pain relief in Children with Musculoskeletal Trauma Clark et al, Paediatrics.
Treatment Resistant Pediatric BD Elham Shirazi M.D. Board of General Psychiatry Board of Child & Adolescent Psychiatry.
METHODS Articles used included children and adolescents ranging in age from infancy to 18 years of age who met the Diagnostic and Statistical Manual of.
BIOLOGICAL THERAPIES FOR DEPRESSION – ELECTROCONVULSIVE THERAPY (ECT) ALICIA.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
Effectiveness of Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Adolescents with Depression Megan Boose, PA-S Evidence Based.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Scottish ECT Audit Network August 2000 Treatment protocols at ECT Dr Grace Fergusson.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.
Journal Club Psychiatry rotation
BIPOLAR DISORDER, DR GIAN LIPPI CONSULTANT PSYCHIATRIST UNIVERSITY OF PRETORIA & WESKOPPIES HOSPITAL FORENSIC UNIT MANAGEMENT GUIDELINES.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Response Without Remission with Right Unilateral Ultrabrief Pulse ECT: Switch to Brief Pulse Unilateral ECT Can be Effective. A Report of Two Cases. Holly.
Date of download: 6/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective, Randomized, Double-blind Comparison.
Objective: To describe the clinical effectiveness and cognitive effects of ECT in a large clinical sample of patients with schizophrenia and explore factors.
A comprehensive evaluation of post- mortem findings and psychiatric case records of individuals who died by probable suicide. A van Laar, J Kielty, M Davoren,
PRESENTACIÓ CORPORATIVA BACKGROUND In order to deinstitutionalize patients with severe mental illness, in 1980 Stein described in USA the model of Assertive.
Consequences Of Non-Compliance To Osteoporosis Medication Among Osteoporotic Women Ankita Modi, Ph.D, M.D. 1, Jackson Tang, M.Sc. 2, Shuvayu Sen, Ph.D.
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
Sedation during mechanical ventilation : A trial of benzodiazepine and opiate in combination Crit Care Med 2006 Vol. 34, No. 5 R2 이윤정 Paul S. Richman,
Prescribing antipsychotics for children and adolescents
Psychiatric Treatment
Seema Jain1, Rebecca Andridge2, Jessica Hellings3
Transcranial direct current stimulation for the acute major depressive episode: a meta-analysis of individual patient data. André R. Brunoni, MD, PhD ;
Pharmacological and Behavioral
Mental Health Western Brabant,
S. Khaldi MD, C. Kornreich MD Phd Service de Psychiatrie.
Efficacy of Paroxetine (Paxil) in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial Case Study presented by: carlo carandang,
OF PHARMACOLOGICAL TREATMENT IN PATIENTS WITH SEVERE MENTAL ILLNESS
A Recommendation from Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from ACOP and APS By Rhys Dela Cruz, Angela Hickey,
Lithium: Clinical Uses and Pharmacokinetics
University of Nizwa College of Pharmacy and Nursing School of Pharmacy
Treatment and Management of Suicide Risk: Available Treatments
Lamotrigine Is Not Slow
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Presentation transcript:

Clinical Effectiveness and Cognitive Impact of Electroconvulsive Therapy for Schizophrenia: A Large Retrospective Study Tyler S. Kaster MD, Zafiris J. Daskalakis MD PhD, and Daniel M. Blumberger MD MSc Centre for Addiction and Mental Health Department of Psychiatry, University of Toronto International Society for ECT and Neuromodulation Atlanta, Georgia May 15, 2016

Disclosures No financial support for this study TSK – None DMB – Non-salary operating funds from Brainsway Ltd. – In-kind equipment support from Brainsway Ltd. and Tonika/Magventure – Site principal investigator for clinical trials from Brainsway Ltd. ZJD – Non-salary operating funds from Brainsway Ltd. – In-kind equipment support from Brainsway Ltd. – Advisory board of Hoffmann-La Roche Limited and Merck – Speaker support from Sepracor and Eli Lilly

Learning Objectives At the conclusion of this activity, the participant will be able to: 1.Describe the rate of treatment response to ECT in patients with schizophrenia 2.Identify clinical and treatment characteristics associated with response to ECT for patients with schizophrenia 3.Describe the rate of cognitive impairment from ECT in patients with schizophrenia

Introduction

Treatment Resistant Schizophrenia Clozapine is the only evidence based treatment with superior efficacy (Lehman 2004) – Difficulties with tolerability, side effects or non- compliance No evidence-based pharmacologic adjunctive or augmentation therapies for treatment-resistant schizophrenia (Taylor 2009, Sommer 2012)

Electroconvulsive Therapy (ECT) Recent Cochrane review concluded: – “ECT combined with treatment with antipsychotic drugs may be considered an option for people with schizophrenia.” (Tharyan and Adams 2005) Recent randomized control trial found a 50% response rate when ECT added to clozapine (Petrides 2015)

Limitations of Current Evidence Most studies used typical antipsychotics in conjunction with ECT (Chanpattana 1999, Chanpattana 1999, Chanpattana & Sackeim 2010) Minimal data on the use of modern ECT technology (i.e. ultra-brief pulse width) (Pisveic 1998) A variety of cognitive rating scales have been used with conflicting results (Tharyan & Adams 2005)

Study Objectives 1)Determine clinical effectiveness and cognitive impact of ECT in a clinical sample of patients with schizophrenia 2)Determine factors associated with ECT treatment response and adverse cognitive effects.

Methods

Study Design & Subjects Conducted at the Centre for Addiction and Mental Health in Toronto, Canada Retrospective chart review all patients referred to ECT treatment program between October 2009 – August 2014 (n=171) Inclusion criteria: – DSM-IV diagnosis of schizophrenia or schizoaffective disorder – At least one acute course of ECT

ECT Technique Device was MECTA spECTrum 5000Q Electrode placement determined by consultant ECT psychiatrist based on clinical factors such as: – risk of cognitive side effects need for rapid response, and previous treatment protocols – Generally BL electrode placement was selected based on literature (Kellner et al., 2010)

ECT Technique Electrode Placement Pulse width (ms)Current (mA) Bilateral (BL) Right unilateral (RUL) Right unilateral- ultrabrief (RUL-UB) 0.3 –

ECT Technique Seizure threshold – determined by stimulation titration method – stimulus intensity set at 1.5 times the seizure threshold Adequate seizure = 15 seconds of peripheral motor manifestation Anaesthetic agent: methohexital mg/kg IV Muscle relaxant: succinycholine mg/kg IV

Assessment of Treatment Response Estimated the clinical global impression improvement (CGI) from patient’s chart: 1.Excellent: dramatic benefit from ECT Treatment 2.Good: patient responded well 3.Moderate: patient received some benefit 4.Poor: patient had minimal to no benefit Response = 1 or 2 Non-response = 3 or 4

Validation of Treatment Response Subset of patients (n=89) had physician rated CGI score available Good inter-rater agreement between chart estimate of CGI and physician rated CGI (kappa=0.7597)

Assessment of Cognitive Impairment Subset of patients (n=89) had physician rated cognitive impairment on following scale: 1.None 2.Mild – no functional impairment 3.Moderate – functional impairment 4.Severe – significant functional impairment Non-significant impairment = 1 or 2 Significant impairment = 3 or 4

Assessment of Cognitive Impairment Attempted to estimate cognitive impairment from chart – 62% of charts did not reference cognitive impairment

Results

Table 1. Patient demographic and treatment features of the treatment cohort (n=171) Demographic/Clinical Age ± SD [Max-Min] (years)45 ± 14.0 [ ] Male gender (%)105 (61.4) Schizophrenia Diagnosis (%)100 (58.4) Schizoaffective Diagnosis (%)71 (41.5) Lacked capacity to consent to ECT (%)102 (59.6) Medications Oral/Depot antipsychotic (%)169 (98.8) Depot antipsychotic (%)56 (32.7) Clozapine antipsychotic (%)82 (47.9) Benzodiazepine use (%)33 (19.3) Antidepressant treatment (%)51 (29.8) Mood stabilizer/AED treatment (%)24 (14.0) Treatment Setting Inpatient (%)163 (95.3) Voluntary Inpatient (%)82 (50.2) Outpatient (%)8 (4.7)

ECT Outcome 76.7% of ECT courses resulted in treatment response

Table 2. ECT treatment details of the treatment cohort (n=171) ECT Indication Failed pharmacotherapy (%)125 (73.1) Prior good response to ECT (%)54 (31.5) Suicidality (%)28 (16.3) Failed continuation maintenance pharmacotherapy (%)26 (15.2) Violent behaviour (%)23 (13.4) Intolerance of adequate pharmacotherapy (%)20 (11.7) Patient preference (%)16 (9.3) ECT Electrode Placement BL (%)147 (86.0) BL  RUL (%) 5 (2.9) RUL (%)11 (6.4) RUL  BL (%) 8 (4.7) RUL-UB (% of RUL courses)9 (37.5) Multiple Treatment Courses Two Courses (%)23 (13.4) Three Courses (%)4 (2.3) Other Mean number of treatments ± SD [Min-Max]12.2 ± 6.5 [1 - 38] Previous ECT (%)72 (42.1) Referred for maintenance treatment (%)77 (45.0) Discharged within 31 days of treatment completion (%)73 (44.8)

Table 3. Factors associated with treatment response to ECT (n=168) Treatment Response (n=129) Non-treatment response (n=39) P-value Referral Indication Failed pharmacotherapy (%)90 (69.8)35 (89.7)0.012 Prior good response to ECT (%)47 (36.4)6 (15.4)0.017 Suicidality (%)20 (15.5)8 (20.5)0.47 Failed continuation maintenance pharmacotherapy (%) 21 (16.3)5 (12.8)0.80 Violent behaviour (%)19 (14.7)4 (10.3)0.60 Intolerance of adequate pharmacotherapy (%)14 (10.9)6 (15.4)0.41 Patient preference (%)12 (9.3)4 (10.3)1

Table 3. Factors associated with treatment response to ECT (n=168) Treatment Response (n=129) Non-treatment response (n=39) P-value Demographic/Clinical Mean age (years) Schizophrenia diagnosis (%)72 (55.8)26 (66.7)0.27 Catatonia (%)7 (5.4)3 (7.7)0.70 Medications during ECT Clozapine (%)62 (48.1)20 (51.3)0.85 Mood Stabilizer/AED (%)14 (10.9)10 (25.6)0.034 AED (%)5 (3.9)7 (17.9)0.007 Lithium (%)9 (7.0)5 (12.8)0.32 Benzodiazepine use (%)23 (17.8)9 (23.1)0.49 Benzodiazepine dose >= 2mg lorazepam equivalent (%) 8 (6.2)4 (10.3)0.48

Table 3. Factors associated with treatment response to ECT (n=168) Treatment Response (n=129) Non-treatment response (n=39) P-value ECT Characteristics First treatment course (%)105 (81.4)36 (92.3)0.14 Mean number of treatments <=6 Treatments (%)25 (19.4)9 (23.1)0.65 BL Treatment (%)114 (88.4)39 (100)0.02

ECT Outcome 76.7% of ECT courses resulted in treatment response 9.0% of patients developed clinically significant cognitive impairment

Table 4. Factors associated with cognitive impairment after ECT (n=89) No cognitive impairment (n=81) Cognitive impairment (n=8) P-value Demographic/Clinical Mean age (years) Medications Mood Stabilizer/AED (%)10 (12.3)0 (0)0.59 AED (%)4 (4.9)0 (0)1 Lithium (%)8 (9.9)0 (0)1 Benzodiazepine use (%)15 (18.5)0 (0)0.34 Benzodiazepine dose >=2mg lorazepam equivalent (%) 7 (8.6)0 (0)1 ECT Characteristics Mean number of treatments <=6 Treatments (%)12 (14.8)0 (0)0.59 BL Treatment (%)71 (87.7)8 (100)0.59

Discussion

Factors associated with treatment response – Anti-epileptic drug treatment – Previous good response to ECT – Failed pharmacotherapy – Electrode placement Factors NOT associated with treatment response – Benzodiazepine use – Clozapine treatment

Discussion No factors associated with cognitive impairment Limited number of patients with clinically significant cognitive impairment (n=8)

Limitations Retrospective study Coarse outcome measure for CGI estimate and cognitive impairment

Future Work Prospective trials using validated scales Maintenance ECT Treatment biomarkers Optimizing ECT parameters New technologies with similar efficacy, but reduced cognitive burden

Conclusion ECT – effective for acute treatment – associated with relatively minimal cognitive impairment in patients with schizophrenia Factors associated with treatment response may aid in selecting patients for ECT Future work is required to determine factors associated with cognitive impairment

Appendix 1. Treatment response agreement (kappa = ) between clinical note CGI and clinician CGI (n=89) Clinical Note CGI 1234 Clinician CGI

Clinical Note CGIN% No records3NA Clinician CGIN%